Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 17,48€(+66,48%). Der Median liegt bei 17,48€(+66,48%).
Kaufen | 2 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Jefferies Global Health Care Conference in New York, NY:» Mehr auf globenewswire.com
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant improvement over standard of care MENLO PARK, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-002, the Company's novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-17A and IL-17F (IL-17A/F).» Mehr auf globenewswire.com
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in 2H 2026 that will provide multiple opportunities to show differentiation over standard of care ORKA-002, targeting IL-17A/F, Phase 1 initiation accelerated to 2Q 2025, with initial PK data now expected around YE 2025; data will support both ORKA-002 and ORKA-021 psoriasis studies Strong cash position of $373 million provides runway through 2027, over one year past anticipated ORKA-001 Phase 2a data in psoriasis MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today reported first quarter 2025 financial results and provided a corporate update.» Mehr auf globenewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | −14,79k | 15,99% |
Nettoeinkommen | −19,41 Mio | 942,75% |
EBITDA | −19,40 Mio | 951,90% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 398,95 Mio€ |
Anzahl Aktien | 37,44 Mio |
52 Wochen-Hoch/Tief | 45,73€ - 4,80€ |
Dividendenrendite | 13,81% |
Dividenden TTM | 1,45€ |
Beta | -0,42 |
KGV (PE Ratio) | −6,74 |
KGWV (PEG Ratio) | −0,34 |
KBV (PB Ratio) | 1,39 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Name | Oruka Therapeutics Aktie |
CEO | Dr. Lawrence Otto Klein Ph.D. |
Mitarbeiter | 28 |
Ticker Symbole
Börse | Symbol |
---|---|
München | HQ1.MU |
Frankfurt | HQ1.F |
Düsseldorf | HQ1.DU |
NASDAQ | ORKA |
Assets entdecken
Shareholder von Oruka Therapeutics Aktie investieren auch in folgende Assets